Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 10, 2022
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
Wed, November 9, 2022
[ Wed, Nov 09th 2022
] - WOPRAI
[ Wed, Nov 09th 2022
] - WOPRAI
[ Wed, Nov 09th 2022
] - WOPRAI
[ Wed, Nov 09th 2022
] - WOPRAI
Andrew Fein Maintained (STRO) at Strong Buy with Decreased Target to $20 on, Nov 9th, 2022
Andrew Fein of HC Wainwright & Co., Maintained "Sutro Biopharma, Inc." (STRO) at Strong Buy with Decreased Target from $30 to $20 on, Nov 9th, 2022.
Andrew has made no other calls on STRO in the last 4 months.
There is 1 other peer that has a rating on STRO. Out of the 1 peers that are also analyzing STRO, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Asthika Goonewardene of "Truist Securities" Maintained at Strong Buy with Decreased Target to $21 on, Tuesday, August 23rd, 2022
